$80.99
+1.94 (+2.45%)
Last updated: Apr 20, 2026 05:36
Fundamentals Overview
Edwards Lifesciences Corporation is in the middle of its 52-week range with premium valuation, trending upward today.
Valuation premium
Intrinsic value (DCF)
-22.2% downside vs price
Profitability
Risk (Beta)
0.95 — in line vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: B · Sentiment improving (2 upgrades)
Pressures (Sell):
DCF 22.2% downside vs price · 3M vs S&P 500: -6.7%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 10, Hold: 6, Neutral: 4, Outperform: 3, Overweight: 7.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $63.00; current price is $80.99. That’s a -22.2% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 44.03 |
| DCF value (model) | $63.00 (-22.2% vs price) |
| PEG (TTM) | N/A |
| P/B (TTM) | 4.55 |
| P/S (TTM) | 7.75 |
| P/FCF (TTM) | 35.24 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 3.72 |
| Quick Ratio (TTM) | 3.09 |
| Cash Ratio (TTM) | 1.62 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 17.64% |
| Gross margin (TTM) | 78.11% |
| Operating margin (TTM) | 26.72% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for EW.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Mizuho | maintain | Outperform | Outperform | 2026-04-13 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-04-06 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-02-11 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-11 |
| BTIG | maintain | Buy | Buy | 2026-02-11 |
| Goldman Sachs | maintain | Buy | Buy | 2026-02-11 |
| Truist Securities | maintain | Hold | Hold | 2026-02-11 |
| Stifel | maintain | Buy | Buy | 2026-01-20 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-01-20 |
| Barclays | maintain | Overweight | Overweight | 2026-01-12 |
| UBS | maintain | Neutral | Neutral | 2026-01-12 |
| TD Cowen | upgrade | Hold | Buy | 2026-01-09 |
| Stifel | maintain | Buy | Buy | 2026-01-07 |
| JP Morgan | upgrade | Neutral | Overweight | 2025-12-18 |
| Canaccord Genuity | maintain | Hold | Hold | 2025-12-17 |
| Baird | maintain | Neutral | Neutral | 2025-12-16 |
| Citigroup | maintain | Buy | Buy | 2025-12-11 |
| Barclays | maintain | Overweight | Overweight | 2025-12-08 |
| UBS | maintain | Neutral | Neutral | 2025-12-05 |
| Canaccord Genuity | maintain | Hold | Hold | 2025-12-05 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-12-05 |
| RBC Capital | maintain | Outperform | Outperform | 2025-12-05 |
| Stifel | maintain | Buy | Buy | 2025-12-05 |
| Baird | maintain | Neutral | Neutral | 2025-12-05 |
| BTIG | maintain | Buy | Buy | 2025-12-05 |
| Truist Securities | maintain | Hold | Hold | 2025-12-05 |
| BTIG | maintain | Buy | Buy | 2025-11-25 |
| Canaccord Genuity | maintain | Hold | Hold | 2025-11-03 |
| Truist Securities | maintain | Hold | Hold | 2025-11-03 |
| Goldman Sachs | maintain | Buy | Buy | 2025-10-31 |